Aquestive Therapeutics, Inc. (AQST): Jefferies Global Healthcare Conference November 16, 2026

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Regulation FD Disclosure. Jefferies Global Healthcare Conference November 16, 2026 © 2026 Aquestive Therapeutics, Inc. Disclaimer 2 This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive,” the “Company,” “we,” “our” or “us”) and contain “forwa

Original reporting
Published Nov 16, 2026, 11:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:41 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AQST
Neutral
low confidence
Mentioned
$AQST
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AQSTNeutralLow
01

Why it matters

No immediate price catalyst; the filing serves as a formal update of expectations.

02

Market read

Limited short‑term relevance; longer‑term impact depends on FDA decisions and funding execution.

03

What to watch

Potential future funding contingent on FDA approval could become material if milestones are met.

Relevance 4/10Novelty 2/10Timing: same day filing

Background

The company presented at the Jefferies Global Healthcare Conference and filed a Regulation FD disclosure outlining its expectations for product approvals and financing.

Company-level read

Ticker impact

$AQSTNeutralLow confidence
Context

SEC Form 8‑K filing discloses forward‑looking statements about regulatory timelines, funding and commercial plans for Anaphylm and other pipeline assets.

Expected impact

likely limited movement as investors await concrete regulatory outcomes.

Evidence & confidence

Without specific data or commitments, the market is unlikely to price in significant changes from this disclosure alone.

Market effects

minimal impact on biotech sector until regulatory milestones are reached.

none

none

Counterpoint

Investors may view the extensive forward‑looking language as a sign of uncertainty and hold off on positions.

Key entities

  • Aquestive Therapeutics, Inc.

    Biopharma developing epinephrine delivery products.

Related articles

$AQSTMed

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

$AQSTMed

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

$AQSTMed

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 • Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic

$AQSTHigh

A dissolving film could become the first oral rescue medicine for severe allergies.

Aquestive Therapeutics (AQST) announced its Q3 2026 financial results and provided updates on its pipeline. The FDA accepted the resubmission of Anaphylm, an oral epinephrine product for severe allergies, with a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for anaphylaxis. The company is also progressing with commercial preparations and international filings.

$AQSTMed

H.C. Wainwright reiterates Aquestive stock rating on FDA review

H.C. Wainwright reiterated a Buy rating and $10 price target for Aquestive Therapeutics (AQST) after the FDA accepted its drug candidate resubmission. AQST shares are down 15% this week but analysts see undervaluation. The company reported Q2 revenue of $13.82M, up 38% YoY, but a wider loss per share than expected. Cantor Fitzgerald also reiterated an Overweight rating with an $11 target.